Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
CRL's Q3 Earnings Top Estimates, Revenues Decline Y/Y, Stock Falls
10:25am, Wednesday, 05'th Nov 2025
Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.
Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates
09:11am, Wednesday, 05'th Nov 2025
Charles River Laboratories (CRL) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $2.59 per share a year ago.
Charles River raises annual profit forecast on stabilizing biotech demand
07:34am, Wednesday, 05'th Nov 2025
Contract drug developer Charles River Laboratories on Wednesday raised its annual profit forecast after posting strong third-quarter results, helped by stabilized demand for its drug discovery and dev
Charles River Laboratories Provides Update on Strategic Review
07:01am, Wednesday, 05'th Nov 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Update on Strategic Review.
Charles River Laboratories Announces Third-Quarter 2025 Results
07:00am, Wednesday, 05'th Nov 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Third-Quarter 2025 Results.
Sumitomo Mitsui Trust Group Inc. Acquires 2,340 Shares of Charles River Laboratories International, Inc. $CRL
04:11am, Saturday, 01'st Nov 2025
Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 109.3% in the second quarter, according to the company in its most recent 1
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:06am, Wednesday, 29'th Oct 2025
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investi
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached
Here's How Charles River Stock Is Placed Ahead of Q3 Earnings
09:55am, Friday, 24'th Oct 2025
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development
08:00am, Wednesday, 22'nd Oct 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibod
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Monday, 20'th Oct 2025
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities
08:00am, Monday, 20'th Oct 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded lib
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption
08:00am, Wednesday, 15'th Oct 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces Scientific Advisory Board, led by Dr. Namandjé N. Bumpus, to support industry adoption of NAMs.
3 Medical Service Industry Stocks Poised to Counter Workforce Issues
12:51pm, Friday, 10'th Oct 2025
Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.
